We read with interest the article entitled “Retrospective analysis of the microbiological spectrum of pneumonia in Turkish patients with lung cancer” by Avci et al. (Contemporary Oncology 2016; 20: 63-66). We are surprised to read that the most frequent isolate from sputum of lung cancer patients with pneumonia was Aspergillus fumigatus [1]. We do understand gram negative bacteria such as Haemophillus influenza and Pseudomonas aeruginosa cause pneumonia in lung cancer patients, but we do not encounter fungal pneumonia in lung cancer patients with usual platinum-based chemotherapy. With regards to the results, we do appreciate hearing from the authors whether lung cancer patients with Aspergillus fumigatus in their sputum had had antimicrobial chemotherapy frequently. For the most important concern, we do wonder whether Aspergillus fumigatus truly caused pneumonia, and whether the antifungal therapy was required for the fungal pneumonia. We do understand the most frequent isolate from sputum was Aspergillus fumigates, however, we do wonder whether it would cause pneumonia. Were there any possibilities of contamination or colonization? We would like to ask the authors what was the definition of “cause of pneumonia” from the bacteriological and clinical point of view.
{"title":"Microbiological spectrum of pneumonia in patients with lung cancer","authors":"T. Tamura, H. Satoh","doi":"10.5114/wo.2016.61570","DOIUrl":"https://doi.org/10.5114/wo.2016.61570","url":null,"abstract":"We read with interest the article entitled “Retrospective analysis of the microbiological spectrum of pneumonia in Turkish patients with lung cancer” by Avci et al. (Contemporary Oncology 2016; 20: 63-66). We are surprised to read that the most frequent isolate from sputum of lung cancer patients with pneumonia was Aspergillus fumigatus [1]. We do understand gram negative bacteria such as Haemophillus influenza and Pseudomonas aeruginosa cause pneumonia in lung cancer patients, but we do not encounter fungal pneumonia in lung cancer patients with usual platinum-based chemotherapy. With regards to the results, we do appreciate hearing from the authors whether lung cancer patients with Aspergillus fumigatus in their sputum had had antimicrobial chemotherapy frequently. For the most important concern, we do wonder whether Aspergillus fumigatus truly caused pneumonia, and whether the antifungal therapy was required for the fungal pneumonia. We do understand the most frequent isolate from sputum was Aspergillus fumigates, however, we do wonder whether it would cause pneumonia. Were there any possibilities of contamination or colonization? We would like to ask the authors what was the definition of “cause of pneumonia” from the bacteriological and clinical point of view.","PeriodicalId":10652,"journal":{"name":"Contemporary Oncology","volume":"6 1","pages":"266 - 266"},"PeriodicalIF":0.0,"publicationDate":"2016-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74378077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aim of this study Chemotherapy-induced peripheral neuropathy (CIPN) is a major complication of cancer patients with chemotherapy. Although many interventions have been evaluated in previous studies, findings are controversial. The aim of this meta-analysis is to assess the efficacy of vitamin E supplementation in preventing CIPN. Material and methods The electronic databases MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were systematically searched from their inception to December 31, 2013 to identify relevant randomised controlled trials. Two reviewers independently scanned and extracted the data of included studies. Review Manager 5.2 was used to analyse data. Results Six articles involving 353 patients were included in meta-analysis. The results showed that vitamin E supplementation did not appear to significantly decrease the incidence of CIPN (relative risk (RR), 0.55; 95% confidence interval (CI), 0.29 to 1.05; p = 0.07), with significant heterogeneity (I2 = 77%). However, Vitamin E supplementation can significantly prevent cisplatin associated neurotoxicity (RR, 0.31; 95%CI, 0.17 to 0.58; p = 0.0002), with no heterogeneity (I2 = 0%). Conclusions Vitamin E administration dose not decrease the incidence of CIPN. However, additional randomised controlled trials using large samples are needed to confirm the role of vitamin E supplementation.
{"title":"Vitamin E does not decrease the incidence of chemotherapy-induced peripheral neuropathy: a meta-analysis","authors":"Hua-ping Huang, M. He, Lihua Liu, Lili Huang","doi":"10.5114/wo.2016.61567","DOIUrl":"https://doi.org/10.5114/wo.2016.61567","url":null,"abstract":"Aim of this study Chemotherapy-induced peripheral neuropathy (CIPN) is a major complication of cancer patients with chemotherapy. Although many interventions have been evaluated in previous studies, findings are controversial. The aim of this meta-analysis is to assess the efficacy of vitamin E supplementation in preventing CIPN. Material and methods The electronic databases MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were systematically searched from their inception to December 31, 2013 to identify relevant randomised controlled trials. Two reviewers independently scanned and extracted the data of included studies. Review Manager 5.2 was used to analyse data. Results Six articles involving 353 patients were included in meta-analysis. The results showed that vitamin E supplementation did not appear to significantly decrease the incidence of CIPN (relative risk (RR), 0.55; 95% confidence interval (CI), 0.29 to 1.05; p = 0.07), with significant heterogeneity (I2 = 77%). However, Vitamin E supplementation can significantly prevent cisplatin associated neurotoxicity (RR, 0.31; 95%CI, 0.17 to 0.58; p = 0.0002), with no heterogeneity (I2 = 0%). Conclusions Vitamin E administration dose not decrease the incidence of CIPN. However, additional randomised controlled trials using large samples are needed to confirm the role of vitamin E supplementation.","PeriodicalId":10652,"journal":{"name":"Contemporary Oncology","volume":"78 1","pages":"237 - 241"},"PeriodicalIF":0.0,"publicationDate":"2016-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90288304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
E. Jodłowska, R. Czepczyński, A. Czarnywojtek, A. Rewers, G. Jarza̧bek, W. Kędzia, M. Ruchała
Similarly to the applications described in the first part of this publication, positron emission tomography with computed tomography (PET/CT) is also gaining importance in monitoring a tumour's response to therapy and diagnosing breast cancer recurrences. This is additionally caused by the fact that many new techniques (dual-time point imaging, positron emission tomography with magnetic resonance PET/MR, PET/CT mammography) and radiotracers (16α-18F-fluoro-17β-estradiol, 18F-fluorothymidine) are under investigation. The highest sensitivity and specificity when monitoring response to treatment is achieved when the PET/CT scan is made after one or two chemotherapy courses. Response to anti-hormonal treatment can also be monitored, also when new radiotracers, such as FES, are used. When monitoring breast cancer recurrences during follow-up, PET/CT has higher sensitivity than conventional imaging modalities, making it possible to monitor the whole body simultaneously. New techniques and radiotracers enhance the sensitivity and specificity of PET and this is why, despite relatively high costs, it might become more widespread in monitoring response to treatment and breast cancer recurrences.
{"title":"The application of positron emission tomography (PET/CT) in diagnosis of breast cancer. Part II. Diagnosis after treatment initiation, future perspectives","authors":"E. Jodłowska, R. Czepczyński, A. Czarnywojtek, A. Rewers, G. Jarza̧bek, W. Kędzia, M. Ruchała","doi":"10.5114/wo.2016.61560","DOIUrl":"https://doi.org/10.5114/wo.2016.61560","url":null,"abstract":"Similarly to the applications described in the first part of this publication, positron emission tomography with computed tomography (PET/CT) is also gaining importance in monitoring a tumour's response to therapy and diagnosing breast cancer recurrences. This is additionally caused by the fact that many new techniques (dual-time point imaging, positron emission tomography with magnetic resonance PET/MR, PET/CT mammography) and radiotracers (16α-18F-fluoro-17β-estradiol, 18F-fluorothymidine) are under investigation. The highest sensitivity and specificity when monitoring response to treatment is achieved when the PET/CT scan is made after one or two chemotherapy courses. Response to anti-hormonal treatment can also be monitored, also when new radiotracers, such as FES, are used. When monitoring breast cancer recurrences during follow-up, PET/CT has higher sensitivity than conventional imaging modalities, making it possible to monitor the whole body simultaneously. New techniques and radiotracers enhance the sensitivity and specificity of PET and this is why, despite relatively high costs, it might become more widespread in monitoring response to treatment and breast cancer recurrences.","PeriodicalId":10652,"journal":{"name":"Contemporary Oncology","volume":"113 1","pages":"205 - 209"},"PeriodicalIF":0.0,"publicationDate":"2016-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89348919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Emiroğlu, Cem Karaali, S. Salimoğlu, I. Sert, C. Aydın
Aim of the study Despite the increase in studies concerning oncoplastic reduction mammoplasty (ORM), data showing long-term aesthetic and patient satisfaction for ORM in patients with macromastia remain limited. Therefore, this study evaluated the long-term results of tumorectomy and concomitant bilateral ORM for early-stage breast cancer patients with macromastia in terms of cosmesis, patient satisfaction, and functional outcomes. Material and methods Retrospective data of patients with macromastia undergoing ORM for breast cancer between 1996 and 2011 were examined and evaluated regarding the aesthetic results, patient satisfaction, and functional outcomes. Results The median age of the 82 patients was 50 years. The median follow-up was 120 months (range: 28–212 months). The median breast volume was 1402 cm3, and the median weight of the excised breast material was 679 g. A good or excellent evaluation of the cosmetic outcome was as follows: self-evaluation: 84.1% at the early-stage, 80.3% at the later stage; panel evaluation: 75.4% at the late-stage. Median patient satisfaction rates were 9.1% for early-stage disease and 8.8% for late-stage disease. Reduced mobility and intertrigo improved by three-fold during the post-operative period. Conclusions ORM for early-stage breast cancer in women with macromastia results in good cosmesis in both the early-stage and long-term, and is quite acceptable for use in patients. Patients reacted favorably to the prospect of having their breast cancer and macromastia treated in a single session, and positive results continued over the long-term.
{"title":"Oncoplastic reduction mammoplasty for breast cancer in women with macromastia: long term aesthetic, functional and satisfaction outcomes","authors":"M. Emiroğlu, Cem Karaali, S. Salimoğlu, I. Sert, C. Aydın","doi":"10.5114/wo.2015.55272","DOIUrl":"https://doi.org/10.5114/wo.2015.55272","url":null,"abstract":"Aim of the study Despite the increase in studies concerning oncoplastic reduction mammoplasty (ORM), data showing long-term aesthetic and patient satisfaction for ORM in patients with macromastia remain limited. Therefore, this study evaluated the long-term results of tumorectomy and concomitant bilateral ORM for early-stage breast cancer patients with macromastia in terms of cosmesis, patient satisfaction, and functional outcomes. Material and methods Retrospective data of patients with macromastia undergoing ORM for breast cancer between 1996 and 2011 were examined and evaluated regarding the aesthetic results, patient satisfaction, and functional outcomes. Results The median age of the 82 patients was 50 years. The median follow-up was 120 months (range: 28–212 months). The median breast volume was 1402 cm3, and the median weight of the excised breast material was 679 g. A good or excellent evaluation of the cosmetic outcome was as follows: self-evaluation: 84.1% at the early-stage, 80.3% at the later stage; panel evaluation: 75.4% at the late-stage. Median patient satisfaction rates were 9.1% for early-stage disease and 8.8% for late-stage disease. Reduced mobility and intertrigo improved by three-fold during the post-operative period. Conclusions ORM for early-stage breast cancer in women with macromastia results in good cosmesis in both the early-stage and long-term, and is quite acceptable for use in patients. Patients reacted favorably to the prospect of having their breast cancer and macromastia treated in a single session, and positive results continued over the long-term.","PeriodicalId":10652,"journal":{"name":"Contemporary Oncology","volume":"49 1","pages":"256 - 260"},"PeriodicalIF":0.0,"publicationDate":"2016-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74764993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Biedka, Tamara Kuźba-Kryszak, T. Nowikiewicz, A. Żyromska
Infertility as a result of antineoplastic therapy is becoming a very important issue due to the growing incidence of neoplastic diseases. Routinely applied antineoplastic treatments and the illness itself lead to fertility disorders. Therapeutic methods used in antineoplastic treatment may cause fertility impairment or sterilization due to permanent damage to reproductive cells. The risk of sterilization depends on the patient's sex, age during therapy, type of neoplasm, radiation dose and treatment area. It is known that chemotherapy and radiotherapy can lead to fertility impairment and the combination of these two gives an additive effect. The aim of this article is to raise the issue of infertility in these patients. It is of growing importance due to the increase in the number of children and young adults who underwent radiotherapy in the past. The progress in antineoplastic therapy improves treatment results, but at the same time requires a deeper look at existential needs of the patient. Reproductive function is an integral element of self-esteem and should be taken into account during therapy planning.
{"title":"Fertility impairment in radiotherapy","authors":"M. Biedka, Tamara Kuźba-Kryszak, T. Nowikiewicz, A. Żyromska","doi":"10.5114/wo.2016.57814","DOIUrl":"https://doi.org/10.5114/wo.2016.57814","url":null,"abstract":"Infertility as a result of antineoplastic therapy is becoming a very important issue due to the growing incidence of neoplastic diseases. Routinely applied antineoplastic treatments and the illness itself lead to fertility disorders. Therapeutic methods used in antineoplastic treatment may cause fertility impairment or sterilization due to permanent damage to reproductive cells. The risk of sterilization depends on the patient's sex, age during therapy, type of neoplasm, radiation dose and treatment area. It is known that chemotherapy and radiotherapy can lead to fertility impairment and the combination of these two gives an additive effect. The aim of this article is to raise the issue of infertility in these patients. It is of growing importance due to the increase in the number of children and young adults who underwent radiotherapy in the past. The progress in antineoplastic therapy improves treatment results, but at the same time requires a deeper look at existential needs of the patient. Reproductive function is an integral element of self-esteem and should be taken into account during therapy planning.","PeriodicalId":10652,"journal":{"name":"Contemporary Oncology","volume":"65 1","pages":"199 - 204"},"PeriodicalIF":0.0,"publicationDate":"2016-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80207375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
G. Pérez-Rodríguez, Catalina Aranda-Moreno, I. Olivares-Corichi, J. García-Sánchez
Aim of the study In breast cancer, oestrogen receptor (ER), progesterone receptor (PgR), and HER2 (HER2/Neu) expression status are used to classify neoplasms into subtypes: Luminal A, Luminal B, HER2/Neu type, and Basallike. The aim of the present study was to establish the molecular subtypes of breast cancers and their association with tumour characteristics and reproductive factors in Mexican women. Material and methods A total of 1326 biopsies of breast tumour tissues were analysed for ER, PR, and HER2/Neu by immunohistochemistry (IHC). Information regarding age, tumour characteristics, and node involvement profiles were collected. Results IHC established that the most common subtype of breast cancer was Luminal A (64.93%), followed by Basal-Like (13.88%), Luminal B (12.52%), and HER2/Neu (8.67%). T2-size tumours (> 2 cm but < 5 cm) were present in 47.59% of all patients. Univariate analysis showed that lymph node positivity (p = 0.009), stage (p = 0.013), and placement of the tumour (p = 0.001) were factors associated with breast cancer subtype. Conclusions Our data show that IHC is useful for distinguishing different subtypes of breast cancer and that Luminal A is the most common breast cancer subtype in the Mexican population. All subtypes were associated with unfavourable clinicopathological features, suggesting that late diagnosis is an important contributor to high mortality rates in the Mexican population.
{"title":"The association of subtypes of breast cancer with tumour characteristics and reproductive factors in 1326 Mexican women","authors":"G. Pérez-Rodríguez, Catalina Aranda-Moreno, I. Olivares-Corichi, J. García-Sánchez","doi":"10.5114/wo.2015.56652","DOIUrl":"https://doi.org/10.5114/wo.2015.56652","url":null,"abstract":"Aim of the study In breast cancer, oestrogen receptor (ER), progesterone receptor (PgR), and HER2 (HER2/Neu) expression status are used to classify neoplasms into subtypes: Luminal A, Luminal B, HER2/Neu type, and Basallike. The aim of the present study was to establish the molecular subtypes of breast cancers and their association with tumour characteristics and reproductive factors in Mexican women. Material and methods A total of 1326 biopsies of breast tumour tissues were analysed for ER, PR, and HER2/Neu by immunohistochemistry (IHC). Information regarding age, tumour characteristics, and node involvement profiles were collected. Results IHC established that the most common subtype of breast cancer was Luminal A (64.93%), followed by Basal-Like (13.88%), Luminal B (12.52%), and HER2/Neu (8.67%). T2-size tumours (> 2 cm but < 5 cm) were present in 47.59% of all patients. Univariate analysis showed that lymph node positivity (p = 0.009), stage (p = 0.013), and placement of the tumour (p = 0.001) were factors associated with breast cancer subtype. Conclusions Our data show that IHC is useful for distinguishing different subtypes of breast cancer and that Luminal A is the most common breast cancer subtype in the Mexican population. All subtypes were associated with unfavourable clinicopathological features, suggesting that late diagnosis is an important contributor to high mortality rates in the Mexican population.","PeriodicalId":10652,"journal":{"name":"Contemporary Oncology","volume":"1 1","pages":"462 - 466"},"PeriodicalIF":0.0,"publicationDate":"2016-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88505532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hui-yu Wang, Jia Wei, Z. Zou, X. Qian, Bao-rui Liu
Aim of the study The prognostic value of the detection of circulating tumour cells (CTCs) in gastric cancer has been studied intensely in recent years. However, the application of different technologies led to inconsistent results between the studies. Here, we performed a meta-analysis of published studies to summarise the evidence. Material and methods Medline and ISI Web of Knowledge were searched up to March 2013 using “circulating tumor cells” and “gastric cancer” as search terms. Hazard ratio (HR) with 95% confidence intervals (CIs) for prognostic outcomes and clinical characteristics were extracted from each study. Pooled hazard ratios (HR) and odds ratios (OR) were calculated using random or fixed-effects models. Results Twelve studies enrolling 774 patients were included. The combined HR estimate for overall survival (OS), disease-free survival (DFS), and progression-free survival (PFS) were 1.41 (95% CI: 1.28–1.62), 2.99 (95% CI: 2.01–4.45) and 1.64 (95% CI: 1.02–2.62), respectively. Subgroup analysis concerning detection methods and sampling time showed that results of RT-PCR for the OS group and RT-PCR for the DFS group suggest a prognostic significance of CTC detection (pooled HR [95% CI]: 1.45 [1.28–1.65], I2 = 38%, p = 0.13; 2.99 [2.01–4.45], I2 = 0%, p = 0.32). In addition, results of the baseline CTC detection group also indicated a significant prognostic value to predict OS and DFS (pooled HR [95% CI]: 1.47 [1.19–1.82], I2 = 38%, p = 0.14; 2.99 [2.01–4.45], I2 = 0%, p = 0.32). We simultaneously found that the detection of CTCs correlated with pathological stage (pooled OR [95% CI]: 2.95 [1.65–5.28], I2 = 56%, p = 0.03), lymph node status (pooled OR [95% CI]: 2.26 [1.50–3.41], I2 = 37%, p = 0.09), the depth of invasion (pooled OR [95% CI]: 3.21 [1.38–7.43], I2 = 72%, p = 0.002), and distant metastasis (pooled OR [95% CI]: 2.68 [1.25–5.73], I2 = 43%, p = 0.15). Conclusions Detection of CTCs is associated with poorer prognosis in gastric cancer patients.
{"title":"Circulating tumour cells predict survival in gastric cancer patients: a meta-analysis","authors":"Hui-yu Wang, Jia Wei, Z. Zou, X. Qian, Bao-rui Liu","doi":"10.5114/wo.2015.56651","DOIUrl":"https://doi.org/10.5114/wo.2015.56651","url":null,"abstract":"Aim of the study The prognostic value of the detection of circulating tumour cells (CTCs) in gastric cancer has been studied intensely in recent years. However, the application of different technologies led to inconsistent results between the studies. Here, we performed a meta-analysis of published studies to summarise the evidence. Material and methods Medline and ISI Web of Knowledge were searched up to March 2013 using “circulating tumor cells” and “gastric cancer” as search terms. Hazard ratio (HR) with 95% confidence intervals (CIs) for prognostic outcomes and clinical characteristics were extracted from each study. Pooled hazard ratios (HR) and odds ratios (OR) were calculated using random or fixed-effects models. Results Twelve studies enrolling 774 patients were included. The combined HR estimate for overall survival (OS), disease-free survival (DFS), and progression-free survival (PFS) were 1.41 (95% CI: 1.28–1.62), 2.99 (95% CI: 2.01–4.45) and 1.64 (95% CI: 1.02–2.62), respectively. Subgroup analysis concerning detection methods and sampling time showed that results of RT-PCR for the OS group and RT-PCR for the DFS group suggest a prognostic significance of CTC detection (pooled HR [95% CI]: 1.45 [1.28–1.65], I2 = 38%, p = 0.13; 2.99 [2.01–4.45], I2 = 0%, p = 0.32). In addition, results of the baseline CTC detection group also indicated a significant prognostic value to predict OS and DFS (pooled HR [95% CI]: 1.47 [1.19–1.82], I2 = 38%, p = 0.14; 2.99 [2.01–4.45], I2 = 0%, p = 0.32). We simultaneously found that the detection of CTCs correlated with pathological stage (pooled OR [95% CI]: 2.95 [1.65–5.28], I2 = 56%, p = 0.03), lymph node status (pooled OR [95% CI]: 2.26 [1.50–3.41], I2 = 37%, p = 0.09), the depth of invasion (pooled OR [95% CI]: 3.21 [1.38–7.43], I2 = 72%, p = 0.002), and distant metastasis (pooled OR [95% CI]: 2.68 [1.25–5.73], I2 = 43%, p = 0.15). Conclusions Detection of CTCs is associated with poorer prognosis in gastric cancer patients.","PeriodicalId":10652,"journal":{"name":"Contemporary Oncology","volume":"34 9 1","pages":"451 - 457"},"PeriodicalIF":0.0,"publicationDate":"2016-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82790824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
In the period 2006–2010, the National Cancer Registry indicated a gradual increase in the incidence of malignant tumours among men, from 64,092 thousand in 2006 to 70,024 thousand in 2010. In the reference period, the number of deaths due to malignant tumours among men oscillated around 52 thousand. The aim of this study was to analyse the incidence of malignant tumours in the male population of Poland in the period 2006–2010. The study material comprised data obtained from the National Cancer Registry and from the Central Statistical Office, available on the websites of these institutions. The malignant-tumour incidence rate among the male population in 2006–2010 showed a slow but steady growth, while the death rate dropped slightly at the end of 2010. The hypothesis that the cancer-incidence risk grows with age has been proven, and a substantial increase in this risk is observed from the fourth decade of life. The most common malignant tumours in Poland in the analysed period included lung cancer, followed by prostate cancer and colorectal cancer. Future prophylactic and educational programmes should be addressed to men prior to reaching the age of increased cancer risk.
{"title":"An analysis of malignant tumour incidence in the male population of Poland in the period 2006–2010","authors":"Renata Domżał-Drzewicka, Edyta Gałęziowska","doi":"10.5114/wo.2015.56655","DOIUrl":"https://doi.org/10.5114/wo.2015.56655","url":null,"abstract":"In the period 2006–2010, the National Cancer Registry indicated a gradual increase in the incidence of malignant tumours among men, from 64,092 thousand in 2006 to 70,024 thousand in 2010. In the reference period, the number of deaths due to malignant tumours among men oscillated around 52 thousand. The aim of this study was to analyse the incidence of malignant tumours in the male population of Poland in the period 2006–2010. The study material comprised data obtained from the National Cancer Registry and from the Central Statistical Office, available on the websites of these institutions. The malignant-tumour incidence rate among the male population in 2006–2010 showed a slow but steady growth, while the death rate dropped slightly at the end of 2010. The hypothesis that the cancer-incidence risk grows with age has been proven, and a substantial increase in this risk is observed from the fourth decade of life. The most common malignant tumours in Poland in the analysed period included lung cancer, followed by prostate cancer and colorectal cancer. Future prophylactic and educational programmes should be addressed to men prior to reaching the age of increased cancer risk.","PeriodicalId":10652,"journal":{"name":"Contemporary Oncology","volume":"127 1","pages":"474 - 479"},"PeriodicalIF":0.0,"publicationDate":"2016-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85123856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Taxanes, a group of cancer drugs that includes docetaxel and paclitaxel, have become a front-line therapy for a variety of metastatic cancers, but resistance can develop. There are several docetaxel resistance mechanisms in prostate cancer: unfavorable tumor microenvironment, drug efflux pump, alterations in microtubule structure and/or function, and apoptotic defects (e.g. up regulation of Bcl-2 and clusterin or activation of the PTEN/PI3K/mTOR pathway or activation of the MAPK/ERK pathway). MicroRNAs (miRNAs), small regulatory molecules, could also function as a contributor to the resistance of cancer cells to commonly used anti-cancer drugs. Aberrant expressions of miRNAs that can act as tumor suppressors or oncogenes are closely associated with the development, invasion and metastasis of various cancers including prostate cancer. Nearly 50 miRNAs have been reported to be differentially expressed in human prostate cancer so far, but knowledge concerning the effects of miRNAs on the sensitivity to anti-cancer drugs is still limited. The author of the review focus on probable impact of miRNAs on the resistance to docetaxel and paclitaxel. Overexpression of miR-21 increased the resistance of prostate cancer cells to docetaxel by targeting PDCD4, PTEN, RECK, and BTG2. Nevertheless, decreased expressions of tumor suppressors: miR-34a, miR-143, miR-148a and miR-200 family are involved in resistance of anti-cancer drugs by inhibition of apoptosis and activation of signaling pathways. Conclude miRNAs become very attractive target for potential therapeutic interventions.
{"title":"Role of microRNAs in the resistance of prostate cancer to docetaxel and paclitaxel","authors":"E. Kopczynska","doi":"10.5114/wo.2015.56648","DOIUrl":"https://doi.org/10.5114/wo.2015.56648","url":null,"abstract":"Taxanes, a group of cancer drugs that includes docetaxel and paclitaxel, have become a front-line therapy for a variety of metastatic cancers, but resistance can develop. There are several docetaxel resistance mechanisms in prostate cancer: unfavorable tumor microenvironment, drug efflux pump, alterations in microtubule structure and/or function, and apoptotic defects (e.g. up regulation of Bcl-2 and clusterin or activation of the PTEN/PI3K/mTOR pathway or activation of the MAPK/ERK pathway). MicroRNAs (miRNAs), small regulatory molecules, could also function as a contributor to the resistance of cancer cells to commonly used anti-cancer drugs. Aberrant expressions of miRNAs that can act as tumor suppressors or oncogenes are closely associated with the development, invasion and metastasis of various cancers including prostate cancer. Nearly 50 miRNAs have been reported to be differentially expressed in human prostate cancer so far, but knowledge concerning the effects of miRNAs on the sensitivity to anti-cancer drugs is still limited. The author of the review focus on probable impact of miRNAs on the resistance to docetaxel and paclitaxel. Overexpression of miR-21 increased the resistance of prostate cancer cells to docetaxel by targeting PDCD4, PTEN, RECK, and BTG2. Nevertheless, decreased expressions of tumor suppressors: miR-34a, miR-143, miR-148a and miR-200 family are involved in resistance of anti-cancer drugs by inhibition of apoptosis and activation of signaling pathways. Conclude miRNAs become very attractive target for potential therapeutic interventions.","PeriodicalId":10652,"journal":{"name":"Contemporary Oncology","volume":"45 1","pages":"423 - 427"},"PeriodicalIF":0.0,"publicationDate":"2016-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78922598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aim of the study To evaluate the intensity of dejection and self-assessment of quality of life in patients with lung cancer from the start of palliative care until death. Material and methods The study included 63 patients with lung cancer from the start of care until death in palliative medicine centers in Bydgoszcz in 2012–2013. The visual-analogue scale constituting part of the ESAS scale was used to assess dejection, while question number 30 of the EORTC QLQ-C30 was used for self-assessment of quality of life. Results “Moderate” and “very” intense dejection initially occurred in 19 (30%) and 24 (38%), and in the 2nd assessment in as many as 23 (36%) and 30 (48%) patients. Average quality of life deteriorated in this respect by 0.09 in the two-step scale (p = 0.005). Increase in the intensity of “moderate” dejection occurred between the 1st and 3rd assessment. Initially it occurred in 2 (9%) patients and in 14 (66%) during the 3rd assessment. In contrast, the levels of “very” severe dejection did not change significantly between the 1st and the 3rd assessment. The average quality of life deteriorated by 0.23 points (p = 0.004). A significant relationship was found only between analgesic treatment and quality of life (p < 0.0005). Other factors such as age, time from diagnosis to start of treatment, place of residence, sex, or financial condition did not affect the quality of life. Conclusions Self-assessment of the quality of life worsens with time. The intensity of dejection does not change in the last 3 weeks of life. In multivariate analysis, among the selected variables such as age, sex, place of residence, time from diagnosis to start of palliative care, financial condition, and type of painkillers used, only the latter has an impact on self-assessed quality of life.
{"title":"Dejection and self-assessment of quality of life in patients with lung cancer subjected to palliative care","authors":"A. Nowicki, Paulina Farbicka, M. Krajnik","doi":"10.5114/wo.2015.53250","DOIUrl":"https://doi.org/10.5114/wo.2015.53250","url":null,"abstract":"Aim of the study To evaluate the intensity of dejection and self-assessment of quality of life in patients with lung cancer from the start of palliative care until death. Material and methods The study included 63 patients with lung cancer from the start of care until death in palliative medicine centers in Bydgoszcz in 2012–2013. The visual-analogue scale constituting part of the ESAS scale was used to assess dejection, while question number 30 of the EORTC QLQ-C30 was used for self-assessment of quality of life. Results “Moderate” and “very” intense dejection initially occurred in 19 (30%) and 24 (38%), and in the 2nd assessment in as many as 23 (36%) and 30 (48%) patients. Average quality of life deteriorated in this respect by 0.09 in the two-step scale (p = 0.005). Increase in the intensity of “moderate” dejection occurred between the 1st and 3rd assessment. Initially it occurred in 2 (9%) patients and in 14 (66%) during the 3rd assessment. In contrast, the levels of “very” severe dejection did not change significantly between the 1st and the 3rd assessment. The average quality of life deteriorated by 0.23 points (p = 0.004). A significant relationship was found only between analgesic treatment and quality of life (p < 0.0005). Other factors such as age, time from diagnosis to start of treatment, place of residence, sex, or financial condition did not affect the quality of life. Conclusions Self-assessment of the quality of life worsens with time. The intensity of dejection does not change in the last 3 weeks of life. In multivariate analysis, among the selected variables such as age, sex, place of residence, time from diagnosis to start of palliative care, financial condition, and type of painkillers used, only the latter has an impact on self-assessed quality of life.","PeriodicalId":10652,"journal":{"name":"Contemporary Oncology","volume":"6 1","pages":"491 - 495"},"PeriodicalIF":0.0,"publicationDate":"2016-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85674969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：